Form 4 Filing for Kymera Therapeutics, Inc.

Nello Mainolfi, Chief Executive Officer and Director of Kymera Therapeutics, Inc., reported a series of transactions on April 29, 2026, primarily involving the company's Common Stock. These transactions were executed under a Rule 10b5-1 trading plan. Mainolfi acquired 30,000 shares of Common Stock at a price of $2.08 per share. Concurrently, he disposed of a total of 29,900 shares of Common Stock. These sales occurred at weighted average prices ranging from $80.23 to $83.07, with specific transactions reporting average prices of $80.74, $81.70, and $82.45. Additionally, Mainolfi exercised stock options for 30,000 shares of Common Stock, with the underlying shares being fully vested and exercisable. Following these transactions, Mainolfi holds 666,195 shares of Common Stock directly.